Opinion|Videos|January 16, 2025
Alternative Clinical Approaches and Data for Patients not Suitable for 2L CAR T
Author(s)Aimee Merino, MD
Panelists discuss treatment options for patients ineligible for chimeric antigen receptor T-cell therapy in the second-line setting, focusing on the selection of new proteasome inhibitors and/or immune-mediated immunomodulatory drugs vs recycling combination regimens, and reviewing recent data from the APOLLO and IKEMA trials that support the use of combination therapies in relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For patients not suitable to receive chimeric antigen receptor T-cell therapy in the second line, what current/emerging treatments would you consider?
- How do you approach selecting a new proteasome inhibitor and/or immune-mediated immunomodulatory drug vs recycling a combination regimen?
- Briefly comment on recent data in combination regimens that support their use:
- APOLLO trial, DPd vs Pd in patients with relapsed/refractory multiple myeloma (R/R MM)
- IKEMA trial, Isa-Kd vs Kd in patients with R/R MM
Advertisement
Related to this article
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
5